With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innov...
The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.
The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.
More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foste...
Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
An outcomes-based approach for incentives in the pharmaceutical sector would help optimise the entire healthcare systems, Nathalie Moll told EURACTIV.com in an interview.
Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.